The Role of Precision Medicine in Addressing Racial Disparities in Urological Cancers.

What is it about?

The article discusses racial disparities in oncological outcomes resulting from differences in social determinants of health (SDOH) and tumor biology in prostate, bladder, and renal cancers. Precision medicine (PM) aims to provide personalized treatment based on individual patient characteristics and has the potential to reduce these inequities. The evidence suggests addressing SDOH for prostate cancer can reverse racial inequities in oncological outcomes, and similar disparities in bladder and renal cancers exist. Research applying a PM approach to different ethnicities is lacking, but better outcomes have been shown with androgen receptor inhibitors, radium-223, and sipuleucel in African Americans with metastatic castrate-resistant prostate cancer. Exploiting the abscopal effect with targeted radiation therapy and immunotherapy has promise but requires further study, as does defining actionable mutations in specific patient groups to tailor treatments as appropriate. The article concludes by emphasizing the need for further research and recruitment strategies to address the historical underrepresentation of ethnic minorities in clinical trials.

Featured Image

Why is it important?

This research is important because it highlights the significant racial disparities in oncological outcomes for patients with genito-urinary cancers. It emphasizes the need to address social determinants of health (SDOH) and tumor biology to reduce these disparities. Additionally, it explores the potential of precision medicine (PM) in addressing these disparities by providing personalized treatment based on individual patient characteristics. Key Takeaways: 1. Racial disparities in genito-urinary cancers are significant and result from differences in SDOH and tumor biology. 2. Addressing SDOH for prostate cancer can reverse racial inequities in oncological outcomes, but differences in incidence remain. 3. Similar disparities exist for bladder and renal cancers, and achieving parity in SDOH for all races would likely do the same. 4. Precision medicine has the potential to reduce these inequities, but further research is needed to explore its effectiveness in different ethnicities. 5. Underrepresentation of ethnic minorities in clinical trials still exists, and recruitment strategies are needed to address this issue.